Noticias y Actividades de Editas Medicine

Editas Medicine es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Editas Medicine es una empresa que cotiza bajo el símbolo de cotización EDIT (US).

Ver el organigrama con sus 17 ejecutivos principales

Biografías más buscadas en Editas Medicine

• Gilmore O'Neill, Chief Executive Officer and President
• Andrew Hirsch, Director
• Bernadette Connaughton, Director

Recientes movimientos de ejecutivos en Editas Medicine

• Amy Parison que ha sido Vice President, Finance and Corporate Controller, ha ascendido a Chief Financial Officer  (noticia publicada el 21 de marzo de 2025).
• Erick Lucera, Chief Financial Officer, ha dejado la empresa  (noticia publicada el 21 de marzo de 2025).
• Brieana Buckley que ha sido Vice President, Medical Affairs and Patient Advocacy, ha ascendido a Senior Vice President, Development and Program Leadership  (noticia publicada el 21 de marzo de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Editas Medicine.

Editas Medicine tiene 2.340 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Biogen (Estados Unidos).

Popular M&A news in Biotecnología

• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (publicado el 30 de abril de 2025)..
• Deepull acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 29 de abril de 2025).
• Biolinq acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 23 de abril de 2025).

Otros contactos sugeridos en el sector Biotecnología

• Herriot Tabuteau - Chief Executive Officer and Director en Axsome Therapeutics
• Kristina Burow - Director en Scholar Rock
• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Editas Medicine

• Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting | Editas Medicine
• Editas Medicine Announces Chief Financial Officer Transition | Editas Medicine
• Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates | Editas Medicine
• Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March | Editas Medicine
• Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Editas Medicine
• Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Editas Medicine
• Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting | Editas Medicine
• Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years | Editas Medicine
• Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Editas Medicine
• Editas Medicine to Participate in Upcoming Investor Conferences | Editas Medicine
• View more press releases Close

Redes sociales sobre Editas Medicine

• Editas Medicine en Wikipedia, Google News y Yahoo Finance
• Editas Medicine en LinkedIn, Twitter y YouTube